Kuros Biosciences AG
SIX:KURN

Watchlist Manager
Kuros Biosciences AG Logo
Kuros Biosciences AG
SIX:KURN
Watchlist
Price: 28.04 CHF 3.77% Market Closed
Market Cap: 1.1B CHF

Intrinsic Value

The intrinsic value of one KURN stock under the Base Case scenario is 37.95 CHF. Compared to the current market price of 28.04 CHF, Kuros Biosciences AG is Undervalued by 26%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

KURN Intrinsic Value
37.95 CHF
Undervaluation 26%
Intrinsic Value
Price
Base Case Scenario

Valuation History
Kuros Biosciences AG

What is Valuation History?
Ask AI Assistant
What other research platforms think about KURN?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is KURN valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for Kuros Biosciences AG.

Explain Valuation
Compare KURN to

Fundamental Analysis

Company Overview
Loading...
Economic Moat
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about KURN?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Kuros Biosciences AG

Current Assets 56.2m
Cash & Short-Term Investments 18m
Receivables 20.3m
Other Current Assets 17.9m
Non-Current Assets 49.9m
PP&E 3.8m
Intangibles 43.2m
Other Non-Current Assets 2.9m
Current Liabilities 26.2m
Accounts Payable 8.7m
Accrued Liabilities 16.9m
Other Current Liabilities 664.1k
Non-Current Liabilities 6.1m
Long-Term Debt 5.5m
Other Non-Current Liabilities 591.2k
Efficiency

Free Cash Flow Analysis
Kuros Biosciences AG

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Kuros Biosciences AG

Revenue
118.4m CHF
Cost of Revenue
-19.8m CHF
Gross Profit
98.6m CHF
Operating Expenses
-100.7m CHF
Operating Income
-2.1m CHF
Other Expenses
-5.1m CHF
Net Income
-7.1m CHF
Fundamental Scores

KURN Profitability Score
Profitability Due Diligence

Kuros Biosciences AG's profitability score is 37/100. The higher the profitability score, the more profitable the company is.

ROIC is Increasing
Exceptional Gross Margin
ROE is Increasing
Strong 3Y Average Gross Margin
37/100
Profitability
Score

Kuros Biosciences AG's profitability score is 37/100. The higher the profitability score, the more profitable the company is.

KURN Solvency Score
Solvency Due Diligence

Kuros Biosciences AG's solvency score is 67/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Low D/E
Negative Net Debt
Long-Term Solvency
67/100
Solvency
Score

Kuros Biosciences AG's solvency score is 67/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

KURN Price Targets Summary
Kuros Biosciences AG

Wall Street analysts forecast KURN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for KURN is 35.34 CHF with a low forecast of 33.13 CHF and a high forecast of 38.33 CHF.

Lowest
Price Target
33.13 CHF
18% Upside
Average
Price Target
35.34 CHF
26% Upside
Highest
Price Target
38.33 CHF
37% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Kuros Biosciences AG
does not pay dividends
Shareholder Yield

Current shareholder yield for KURN is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y
What is the Intrinsic Value of one KURN stock?

The intrinsic value of one KURN stock under the Base Case scenario is 37.95 CHF.

Is KURN stock undervalued or overvalued?

Compared to the current market price of 28.04 CHF, Kuros Biosciences AG is Undervalued by 26%.

Back to Top